Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer
about
Optimized tumor cryptic peptides: the basis for universal neo-antigen-like tumor vaccinesNeoantigen-based cancer immunotherapyHarnessing the immune system to improve cancer therapyStable long-term cultures of self-renewing B cells and their applicationsMutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor VaccinationIntegrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicityNovel technologies and emerging biomarkers for personalized cancer immunotherapyCD8⁺ T Cell-Independent Immune-Mediated Mechanisms of Anti-Tumor ActivityInterest of Tumor-Specific CD4 T Helper 1 Cells for Therapeutic Anticancer VaccineTrial Watch: Adoptive cell transfer for oncological indicationsEnhancing Cancer Immunotherapy Via Activation of Innate ImmunityAdoptive T-cell therapy for cancer: The era of engineered T cellsEvolving immunotherapy strategies in urothelial cancerAcquired and intrinsic resistance in cancer immunotherapyAdoptive T-cell therapy for LeukemiaToxicities of Immunotherapy for the PractitionerTo affinity and beyond: harnessing the T cell receptor for cancer immunotherapyCancer vaccinesImmune escape mechanisms as a guide for cancer immunotherapyTherapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1.AACR Cancer Progress Report 2014High-content molecular profiling of T-cell therapy in oncologyImproving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer VaccinationImmunotherapy for Gastroesophageal CancerPD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinationsExploiting IL-17-producing CD4+ and CD8+ T cells to improve cancer immunotherapy in the clinicT-cell receptor gene therapy--ready to go viral?TCR affinity for p/MHC formed by tumor antigens that are self-proteins: impact on efficacy and toxicityTumor neoantigens: building a framework for personalized cancer immunotherapyFrom mice to humans: developments in cancer immunoeditingPOLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial CancerBET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy modelsCancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancerGenetic basis for clinical response to CTLA-4 blockade in melanomaBeyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors.CD4+ T-cell epitope prediction using antigen processing constraintsT-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.Biopolymer implants enhance the efficacy of adoptive T-cell therapy.T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer.Twelve-year survival and immune correlates in dendritic cell-vaccinated melanoma patients.
P2860
Q26738680-8FBF8051-247F-4BC5-BDE3-39E7C712D9D1Q26738693-4377539E-748C-4263-997C-69B8042771CCQ26738698-6FA6901E-116D-4195-A157-68AAEFB31999Q26766723-3F747B29-8A4D-4FED-8D65-BF2CDAA1F310Q26769044-0B585FC7-4B48-4C66-AA99-8736F551FEBDQ26769744-6BE27EF8-7A8E-475D-9682-5E2B4DF89A77Q26770780-2E9F5987-9930-4E92-92A9-62794DAFD197Q26782520-B6A0DD85-3C6E-4386-914C-455B200ED141Q26782583-695969DB-CA04-4611-AA5E-77A38EEA58F8Q26785545-3C5ADCB0-89EE-48EF-84A6-2BCC79B6942DQ26796313-C738F6A0-8623-4848-8C6D-565351A429D2Q26800611-CBA2C25B-6E2C-402E-9E43-08BD43FB4B96Q26823557-D0F30F54-CD26-4ECD-B4FF-FE90A7877717Q26827701-7F91DB9E-9447-4757-BB46-182A48F6827BQ27006934-4866E461-3884-4100-AAD8-A8B1687FCB13Q27008140-D1F05CF9-FE24-4AE2-86D2-866F50200252Q27008423-07884C1A-3D97-4379-890B-94B21895744AQ27024438-33C56D65-06AD-4EB4-917C-E8BCAA0B97CFQ27024502-31851CC2-EEAA-456C-B448-03DFF0AED0B1Q27313856-070B44CD-0105-4E3E-B670-1D3083AC1BA4Q27346723-A9AE9276-D3AB-4D07-94EC-9C499416D3F1Q28066792-47969665-8DF5-418F-B2F1-1CAB5A500F1CQ28068378-253C3C8E-2A4D-4ADC-8D9E-43C60E1A7571Q28069873-3419CF89-3660-459F-A88C-D3E9634A4314Q28075712-9C229021-C794-4C30-B164-E3904FE9A688Q28075992-A416FE03-621A-4757-947D-D7788FFEE1ABQ28081611-BF081C53-E271-498A-A953-41B587C58FA6Q28081699-BC34AF0A-20A9-4800-8173-6160C50A22D3Q28082704-1E7216C9-AA0E-4A9B-91C3-5D2B16E4E423Q28088304-36DA4FA6-71D9-41F9-A28A-0400E6B98D33Q28260529-E44A7D07-29D8-4DCE-8463-AEBDCA7AFBEDQ28828457-42854F6E-C1E3-4DEA-B4AD-9FF072940FF3Q29615679-208DC5EF-3C8A-48C9-BB8D-B78E09DA9C7DQ29620594-B7847727-D3BE-43DB-8371-5B4192DCD313Q30276874-E3CE9FCB-B7CF-4027-B1E6-21A4FBD171B3Q30384608-C1F48985-6A68-4DC2-8AD7-BE0BB67074DCQ30491565-E3430B44-CF32-4276-A759-387B9C155466Q30614247-305AD984-84AE-4D47-9AC0-B29D9F9ED9D0Q30832820-7475FE1E-D826-4EFD-94B4-722D2491F4B5Q30846001-81D6BC12-7851-4347-A654-1DA0273187C2
P2860
Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer
description
article publié dans la revue scientifique Science
@fr
im Mai 2014 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published in Science
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в травні 2014
@uk
name
Cancer immunotherapy based on ...... patient with epithelial cancer
@en
Cancer immunotherapy based on ...... patient with epithelial cancer
@nl
type
label
Cancer immunotherapy based on ...... patient with epithelial cancer
@en
Cancer immunotherapy based on ...... patient with epithelial cancer
@nl
prefLabel
Cancer immunotherapy based on ...... patient with epithelial cancer
@en
Cancer immunotherapy based on ...... patient with epithelial cancer
@nl
P2093
P2860
P356
P1433
P1476
Cancer immunotherapy based on ...... patient with epithelial cancer
@en
P2093
Christian S Hinrichs
James C Yang
John R Wunderlich
Katherine Hogan
Maria R Parkhurst
Mark E Dudley
Paul F Robbins
Robert P Somerville
Simon Turcotte
P2860
P304
P356
10.1126/SCIENCE.1251102
P407
P577
2014-05-01T00:00:00Z